Eminyakeni yamuva, ukuthengiswa kweapixabanzikhule ngokushesha, futhi imakethe yomhlaba wonke isivele yadlulai-rivaroxaban.Ngoba u-Eliquis (apixaban) inenzuzo kune-warfarin ekuvimbeleni isifo sohlangothi nokopha, kanye ne-Xarelto (I-Rivaroxaban) ibonise kuphela ukungabi ngaphansi.Ngaphezu kwalokho,I-Apixabanayidingi ukulungiswa kwemithamo eyinkimbinkimbi, futhi imithi ilula kakhulu.Lolu chungechunge lwemibi eyabangelwai-rivaroxabanukulahlekelwa indawo emakethe yase-US.

Nokho, ezweni laseChina,i-rivaroxabaninezinkomba eziningi emhlabeni jikelele nasezweni laseChina.Isikhathi sokuphelelwa yisikhathi selungelo lobunikazii-rivaroxabaniseduze, futhi ukutholakala komuthi kuzodala inani labantui-rivaroxabanizidakamizwa ezijwayelekile ukwedlula ngokuphawulekayo lokhoI-Apixaban.

Ngokusho kwedatha ye-Xianda, ukuthengiswa kwemakethe yasekhaya kwe-rivaroxaban ngo-2018 bekungama-yuan ayizigidi eziyizinkulungwane ezingu-2.8.Ngokwesimemezelo se-Huahai Pharmaceutical, ukuthengiswa kwemakethe yesibhedlela yasekhaya yei-rivaroxabanngo-2018 bekungama-yuan ayizigidi eziyizinkulungwane eziyi-1.527.

Kunjalo, ukufakwa ohlwini kwemithi ejwayelekile kuzoholela ekwehleni okukhulu kwentengo yosuku olulodwa lwei-rivaroxaban.Kucatshangelwa ukuthi phakathi kwawo wonke ama-NOAC, amalungelo obunikazi ei-rivaroxabanizinhlanganisela ziphelelwa yisikhathi ngo-2020 ekuqaleni (amalungelo obunikazi weapixabankanye ne-dabigatran etexilate zinde Isikhathi eside), ngokungangabazeki kuzoba nenzuzo ekukhuthazeni ngokugcwelei-rivaroxabanizidakamizwa ezijwayelekile ezithatha indawo ye-warfarin.Uma intengo yansuku zonke yei-rivaroxabanizidakamizwa ezijwayelekile zethulwa zisuka ku-27.6 yuan ziye ku-2.76 yuan, lo mkhuba nawo uzoqiniswa.

Inani lezicelo ezicabangela kuphela iziguli ezine-atrial fibrillation (AF) nalo liyamangalisa.Isibalo seziguli ezine-atrial fibrillation eShayina silinganiselwa ezigidini eziyi-10, ezingaba yizigidi ezi-2 ezenzelwe i-valvular atrial fibrillation kanye nezigidi ezingu-7 ze-non-valvular atrial fibrillation.Inhlolovo yango-2016 Kutholwe ukuthi izinga lokuqwashisa nge-atrial fibrillation e-Mainland China lingama-40%, kanti izinga le-anticoagulation lingu-30%.I-Rivaroxaban ilungele ukusetshenziswa, ayidingi ukuqapha okujwayelekile kwezinkomba ze-coagulation, futhi izinga le-anticoagulation nalo lizothuthukiswa kakhulu.Kubikezelwa ukuthi umuthi ojwayelekile wei-rivaroxabanizoba seMainland China.Usayizi wemakethe osetshenziswa ezigulini ezine-non-valvular atrial fibrillation kanye ne-atrial fibrillation: iziguli eziyizigidi ezingu-7 * 30% izinga le-anticoagulation * 50% izinga lokungena * 2.76 yuan/ngosuku * izinsuku ezingu-365 = 157 million yuan.

Ngaphezu kwalokho, amathuba emakethe okuvimbela nokwelashwa kweziguli ze-VTE abukelwa phansi.Ngokwezibalo ze-VTE Prevention and Treatment Centre e-United States, isibalo seziguli ze-VTE e-United States sifinyelela ku-900,000 unyaka ngamunye, futhi isibalo sabantu abafa nge-VTE sifinyelela ku-60,000 kuya ku-100,000, futhi kukhona izinkinga zesikhathi eside (ezifana ne-DVT) iziguli zibalelwa ku-50%, futhi inani lokubuyela emuva phakathi neminyaka eyi-10 libalelwa ku-33%.

Ngenxa yokuguga kwabantu baseShayina, futhi isizinda sabantu singaphezu kuka-4 kune-United States (abantu abayizigidi eziyizinkulungwane ezingu-1.395).Kungabikezelwa ukuthi kuneziguli ze-VTE eziyizigidi ezingu-3.6 eShayina unyaka ngamunye.Kucatshangwa ukuthi izinga lokwelashwa lezinyanga ezi-3 lika-i-rivaroxabaningu-80%, usayizi wemakethe uthi: iziguli eziyizigidi ezingu-3.6 * 80% izinga lokwelashwa * 2.76 yuan/ngosuku * izinsuku ezingu-92 = 731 million yuan.

Ngakho-ke, kubalwa kuphela izinkomba ezimbili ze-AF ne-VTE, usayizi wemakethe yasekhaya yemithi ejwayelekile ye-rivaroxaban usondele kumayuan ayizigidi eziyizinkulungwane ezimbili.Kwanele ukwenza izinkampani zasekhaya ezithaka imithi zigijimele ukufaka isicelo sokufakwa ohlwini.

Thina,I-Changzhou Pharmaceutical Factory, futhi khiqizaapxiabanfuthii-rivaroxban, futhi bobabili bane-DMF.I-Rivaroxabaningaphansi kokucutshungulwa kokufaka i-CEP kanye ne-WC.